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This communication provides an overview of the current and future  
applications of molecular sonography, emphasizing the principles of the tech-
nique. Molecular sonography is currently used for preclinical assessment of tumor 
detection and response in a variety of models. It has potential clinical applications 
in improved characterization of tumors based on their genomes. Clinical trials 
have been conducted for a variety of neoplastic, inflammatory and immunologic 
abnormalities.
Keywords: Labeled microbubbles, molecular characterization and detection, 
assessment of tumor response, ultrasonography
1. Introduction
Molecular imaging describes a relatively new imaging technique that depicts 
molecular processes rather than anatomic changes that occur in diseased tissue. 
It affords non-invasive imaging on a cellular level based on depiction of selected 
molecular receptors. The premise of molecular imaging is based on the fact that 
molecular events precede anatomic changes, and therefore, have the potential 
to detect neoplastic processes early as well as potentially determine response to 
therapy shortly after its administration. Molecular imaging can depict genomic 
phenotypes, and advantage that proves key to personalizing medical therapy.
There are a variety of modalities currently used to image diseased tissue. PET, 
or Positron Emission Tomography, utilizes radioactive substances known as tracers 
to detect disease. It is noninvasive and can identify areas of high metabolic activity 
that may be concerning for cancer. However, PET’s anatomic clarity is imprecise 
compared to CT/MRI and it remains quite expensive. SPECT, Single Photon 
Emission Tomography, implements a similar mechanism as PET but is appreciably 
cheaper. Additionally, the radio tracers in SPECT have much longer half-lives, 
extending the imaging window. However, SPECT has even lower image resolution 
than PET. MRI, Magnetic Resonance Imaging, does not use radiation and provides 
a snapshot of the patient’s anatomy with excellent resolution. However, it is notably 
time-consuming and expensive.
Molecular sonography holds many advantages over these imaging techniques. In 
addition to its low cost and high spatial resolution, molecular sonography is consid-
ered easy to use and repeatable when compared to most other diagnostic modalities. 
Currently, it is used for evaluation of tumor models. Reports of the use of molecular 
sonography in human subjects have recently been published [1].
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This review will describe the current uses of molecular sonography and discuss 
future directions for research and development.
2. Targeted microbubbles
Microbubbles used for contrast enhanced and molecular sonography consist of 
an encapsulated gas covered by a lipid shell. They range from 2 to 5 microns in size, 
approximately one-third the size of an erythrocyte. As such, they remain intravas-
cular and do not extravasate into the interstitium. They enhance the signal-to-noise 
ratio due to their oscillations in an insonated field as best depicted using harmonics.
A variety of targeting ligands, such as the vasogenic growth factor (VEGF) 
receptor, can be attached to the shell of a microbubble using the streptavidin-biotin 
spacer (Figure 1) [2]. Molecular sonography has been used to evaluate tumor 
angiogenesis, anti-immune encephalomyelitis, inflammatory bowel disease, trans-
plant rejection and abnormal myocardial perfusion. The most frequently utilized 
application of molecular sonography involves a VEGF receptor antibody can be 
used as a ligand on a microbubble to detect tumor microvessels (Figure 2) [3]. This 
has shown to provide early detection of several cancers in murine models, notably 
pancreatic, prostate, and squamous cell carcinoma.
Labeled microbubbles may have an important role in monitoring tumor 
response to anti-angiogenic medications. In a preclinical proof of concept study 
using colon cancer models, 3D molecular sonography showed close correlation with 
treatment response to antiangiogenetic therapy [4].
Microbubble sonography can be used to assess the potential efficacy of specific 
anti-angiogenetic medications. In a pilot study of patients with refractory hepato-
cellular carcinomas, we found that a significant decrease in vascularity was seen 
in responsive vs. non-responsive tumors in the first 15 days after treatment was 
initiated (Figure 3) [5].
Similarly, molecular sonography has been studied as a means to evaluate acute 
ileitis in a swine model that targeted E- and P-selectin. The intensity of the sono-
graphic signal correlated to the amount of immunofluorescence [6].
Figure 1. 
Drawing showing the streptavidin/biotin spacer for attachment of anti-VEGF receptor to microbubble.
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3. Potential clinical applications
The main potential clinical application of labeled microbubbles includes early 
detection of tumors, monitoring tumor response, assessment of inflammation and/
or ischemia, early detection of transplant infection and potential for targeted drug 
delivery.
One of the challenges to use these microbubbles is their fabrication for clinical 
use. Specifically, the immunogenicity of the streptavidin used for attaching the 
ligand to the bubble requires that it be internalized within the microbubble. This is 
only available from a few manufacturers on an investigational basis. We reported 
our early experience developing a labeled microbubble [7].
Only a few studies using labeled microbubbles in humans have been reported 
[1]. The group headed by Willman showed that breast and ovarian malignant 
Figure 2. 
Molecular sonograms of implanted murine tumor with low (top) and high (bottom) VEGF receptors as 
confirmed with immunofluorescence [2].
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tumors had greater signal than benign ones. Specifically, in a study of 24 patients 
with ovarian cancers and 21 with breast lesions, 93% of malignant breast lesions 
and 77% of malignant ovarian cancers demonstrated increased signal [1].
Labeled microbubbles have also been used in detecting prostate cancer and 
sentinel lymph nodes [7, 8]. Molecular lymphosonography was used to detect 
metastatic involvement in a swine melanoma model. Metastatic involvement of 
the sentinel lymph node can distinguish local vs. metastatic disease in women 
with breast cancer. It has also been used in a variety of cancers such as melanoma, 
esophageal, head and neck, stomach and thyroid cancer. Molecular sonography 
using nanobubble targeted prostate specific membrane antigen has been investi-
gated in an orthotopic murine model [8]. Increased extravasation and retention 
were observed in prostate cancer models as well as exhibiting different time/inten-
sity curves (enhancement kinetics) in cancerous tissue.
Angiogenesis, the generation of new blood vessels, has also been extensively 
investigated with molecular sonography due to its role in the development and 
metastatic spread of numerous cancers. It is crucial in the growth of tumors and 
subsequent metastasis. VEGFR2 is one of the most studied markers of angiogenesis 
and is over expressed on tumor-associated endothelial cells [9]. In one study of a 
transgenic mouse model, microbubbles targeting VEGFR2 showed an increased 
contrast-enhanced ultrasound signal from hyperplasia to ductal carcinoma in situ 
and breast cancer compared to normal breast tissue [10]. In another study of laying 
hens, a microbubble targeting αvβ3 integrin sensitively detected ovarian cancer 
Figure 3. 
Time intensity curve in responsive (top) vs. non-responsive (bottom) hepatocellular cancer treated with  
anti-angiogenic medications.
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at an early stage [11]. These are just two studies that support the clinical utility of 
angiogenesis targeted microbubbles in early tumor detection.
Applying the principles of molecular sonography to atherosclerosis can help 
identify at-risk plaques before acute events occur, potentially enabling prevention 
of evolution into irreversible damage. Normally, patients do not exhibit symptoms 
until an episode of severe stenosis or rupture occurs; thus, there is valuable utility in 
monitoring the growth of atherosclerotic plaques. JAM-A is an example of a marker 
that has been linked to early plaque formation and vulnerability [12]. In a study per-
formed on mice that were fed an atherogenic diet, molecular ultrasound of JAM-A 
showed early stages of atherosclerosis and detected acute blood flow variations [13].
Acute cardiac ischemia is another pathology that would benefit from molecu-
lar ultrasound imaging. Current methods of detection such as EKG and cardiac 
MRIs suffer from various shortcomings such as accuracy, convenience, or safety. 
Sonography with labeled microbubbles could resolve a number of these shortcom-
ings when used to identify post-ischemic myocardium. E- and P- selectin are two 
potential markers that were used in murine models to identify ischemic tissue 
shortly after undergoing an ischemic event [14, 15]. While cardiac molecular 
ultrasound imaging has shown promising results regarding safety and efficacy, it is 
technically difficult and highly user-dependent. Further testing needs to be per-
formed to assess its feasibility when compared with current gold standards.
Microbubbles also can be applied in the assessment of inflammatory bowel 
disease (IBD). Two methods of assessing IBD are endoscopy and ultrasound. The 
former requires a procedure under anesthesia, while the latter is restricted by its 
relatively limited sensitivity. Molecular ultrasound holds clinical potential to serve 
as a complementary tool with high sensitivity in the imaging of IBD. One study 
utilized porcine tissue with terminal ileitis imaged with dual E- and P-selectin-
targeted microbubbles. The study concluded that increased ultrasound signal 
correlated well with histologic grades of inflammation [16]. This study highlights 
selectin-targeted ultrasound’s utility to serve as a high-sensitivity adjunctive tool for 
assessment of IBD in the clinical setting.
4. Conclusions
Molecular sonography has great potential as a means to detect early stages of a 
variety of cancers as well as a means to evaluate tumor response. It is anticipated 
that more widespread clinical use will occur in the next few years once these micro-
bubbles become more readily available.
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